San Diego’s $1.7B Tech-Bio Explosion: Takeda and Iambic’s AI Drug Deal Shakes the Industry
The ‘AI Gold Rush’ has officially hit Southern California as Takeda Pharmaceutical commits over $1.7 billion to a multi-year partnership with San Diego’s own Iambic Therapeutics. This high-stakes deal focuses on leveraging proprietary AI models like NeuralPLexer to design breakthrough treatments for cancer and inflammatory diseases. By compressing years of research into months, this partnership proves that San Diego is the global epicenter for the ‘Tech-Bio’ intersection. Curious how AI is reinventing the pharmacy of the future? Read the full breakdown of this industry-shifting agreement on NewsBurrow today!